Table of Contents
Alzheimer’s Disease Therapeutics Market Overview
Alzheimer’s disease therapeutics companies include both symptomatic treatments and disease-modifying therapies.
Symptomatic treatments, such as cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and NMDA receptor antagonists (memantine). Temporarily alleviate cognitive symptoms by enhancing neurotransmitter activity.
Disease-modifying therapies, such as anti-amyloid monoclonal antibodies (lecanemab, donanemab), target amyloid plaques to slow disease progression.
Additionally, research into tau protein modulators and emerging therapies like gene therapy, anti-inflammatory agents, and hormonal/metabolic modulators is ongoing. Aiming to address underlying disease mechanisms and improve long-term outcomes for AD patients.
Market Drivers
The global Alzheimer’s disease therapeutics market is driven by several key factors. Including the rising prevalence of Alzheimer’s due to an aging population.
Advancements in diagnostic technologies that enable early detection, and the development of disease-modifying therapies like lecanemab and donanemab.
Additionally, increased research and development investments, along with growing public and professional awareness, are further fueling market growth. These elements collectively contribute to the expansion of the Alzheimer’s therapeutics market.
Market Size
The Alzheimer’s therapeutics market is expected to rise from USD 5.5 billion in 2023 to USD 30.8 billion by 2033, growing at 18.8% CAGR.
List of Major Companies
These are the top ten companies operating in the Alzheimers Disease Therapeutics Market:
- Biogen
- Merck
- GSK
- Novartis
- Johnson-n-Johnson
- Bristol-Myers-Squibb
- Sanofi
- Pfizer
- Teva-Pharmaceutical
- AbbVie
Biogen
Company Overview
| Establishment Year | 1978 |
| Headquarter | Cambridge, Massachusetts, U.S. |
| Key Management | Chris Viehbacher (CEO) |
| Revenue (US$ Bn) | $ 9.8 Billion (2023) |
| Headcount | ~ 7,570 (2023) |
| Website | https://www.biogen.com/ |
About Biogen
Biogen Inc. has made significant strides in the Alzheimer’s therapeutics field. Notably with the FDA’s accelerated approval of lecanemab (Leqembi) in January 2023.
Developed in partnership with Eisai Co., Ltd., Leqembi targets amyloid beta plaques linked to Alzheimer’s. However, the European Medicines Agency (EMA) rejected its approval in July 2024, citing concerns over its risk-benefit profile.
In July 2023, Biogen acquired Reata Pharmaceuticals for $6.5 billion to strengthen its portfolio in neurological and rare diseases.
The company is also advancing therapies targeting tau proteins, further diversifying its Alzheimer’s treatment strategies.
Geographical Presence
Biogen Inc., headquartered in Cambridge, Massachusetts, is a global leader in biotechnology, specializing in neurological and neurodegenerative disease therapies.
With a strong presence across multiple countries, Biogen operates key offices in the United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, France, Germany, Hungary, India, Italy, Japan, Mexico, the Netherlands, Poland, South Korea, Spain, Sweden, and Switzerland.
This extensive geographical footprint enables the company to effectively develop, distribute, and deliver its therapies to patients around the world.
Recent Developments
- In October 2024, Eisai and Biogen submitted the FDA BLA for the lecanemab-irmb (LEQEMBI®) subcutaneous autoinjector for weekly dosing in Alzheimer’s patients with Mild Cognitive Impairment or mild dementia, receiving Fast Track designation.
- In October 2024, Biogen and Neomorph partnered to develop molecular glue degraders for Alzheimer’s disease using Neomorph’s discovery platform.
Merck
Company Overview
| Establishment Year | 1891 |
| Headquarter | Rahway, New Jersey, U.S. |
| Key Management | Robert M. Davis (CEO) |
| Revenue (US$ Bn) | $ 60.1 B (2023) |
| Headcount | ~ 72,000 (2023) |
| Website | http://merck.com/ |
About Merck
Merck & Co., Inc. has been actively involved in the Alzheimer’s disease therapeutics sector. In August 2022, Merck entered into a strategic collaboration with Cerevance to identify novel targets for Alzheimer’s treatment.
This involves an upfront payment of $25 million and potential milestone payments totaling up to $1.1 billion.
This partnership leverages Cerevance’s proprietary NETSseq technology to discover new therapeutic targets.
In May 2024, the collaboration achieved its first milestone, triggering an undisclosed payment from Merck to Cerevance.
These initiatives underscore Merck’s commitment to advancing Alzheimer’s disease research through strategic partnerships and innovative target discovery.
Geographical Presence
Merck & Co., Inc. (known as MSD outside the U.S. and Canada) operates in approximately 150 countries worldwide.
The company has a significant presence in North America, including the United States and Canada. It maintains a strong footprint across Europe, with operations in Germany, France, the UK, Italy, and Spain.
In the Asia-Pacific region, Merck serves markets such as China, Japan, India, South Korea, and Australia. It is also present in Latin American countries like Brazil, Mexico, Argentina, and Chile and has operations in various countries across the Middle East and Africa.
This global presence allows Merck to address diverse healthcare needs and deliver innovative solutions worldwide.
Recent Developments
- In May 2024, Cerevance announced reaching the first milestone in its research collaboration with Merck, which focused on identifying novel therapeutic targets for Alzheimer’s disease.
- In August 2022, Cerevance announced a multi-year collaboration with Merck to identify novel Alzheimer’s disease targets using its NETSseq technology platform.
GSK
Company Overview
| Establishment Year | 2000 |
| Headquarter | London, England, UK |
| Key Management | Emma Walmsley (CEO) |
| Revenue (US$ Bn) | $ 37.7 Billion (2022) |
| Headcount | ~ 70,000 (2024) |
| Website | https://www.gsk.com/ |
About GSK
GSK plc is engaged in the Alzheimer’s disease therapeutics sector through strategic collaborations and research initiatives.
In July 2021, GSK entered into a global collaboration with Alector to co-develop monoclonal antibodies AL001 and AL101, targeting neurodegenerative diseases.
Including Alzheimer’s, with Alector receiving $700 million upfront and potential milestone payments of up to $1.5 billion.
In July 2024, GSK presented new data at the Alzheimer’s Association International Conference. Providing genetic evidence supporting the therapeutic hypothesis of AL101 and its phase II trial in Alzheimer’s disease.
Additionally, GSK’s shingles vaccine, Shingrix, has been associated with a reduced risk of dementia. Suggesting potential implications for Alzheimer’s prevention strategies.
These developments underscore GSK’s commitment to advancing Alzheimer’s disease therapeutics through innovative research and strategic partnerships.
Geographical Presence
GSK plc, headquartered in London, operates globally across four primary regions: Europe, North America, International, and Emerging Markets.
In Europe, the company maintains a strong presence, particularly in the UK, Germany, France, and Spain. In North America, GSK has significant operations in the United States and Canada.
Internationally, GSK serves regions like Latin America, the Middle East, and Africa, with manufacturing sites in countries such as Brazil and South Africa.
The company is also expanding in emerging markets through strategic acquisitions. GSK operates 74 manufacturing sites and large R&D centers worldwide, underscoring its broad geographical footprint and commitment to global healthcare solutions.
Recent Development
- In October 2024, GSK partnered with Boston University and Boston Medical Center to create new models for studying lung diseases like pulmonary fibrosis.
- In July 2021, GSK and Alector partnered to develop two monoclonal antibodies, AL001 and AL101, to elevate progranulin (PGRN) levels, a key immune regulator linked to neurodegenerative disorders.
Novartis
Company Overview
| Establishment Year | 1996 |
| Headquarter | Basel, Switzerland |
| Key Management | Vasant Narasimhan (CEO) |
| Revenue (US$ Bn) | $ 45.4 Billion (2023) |
| Headcount | ~ 76,057 (2023) |
| Website | https://novartis.com/ |
About Novartis
Novartis is involved in Alzheimer’s disease therapeutics, focusing on innovative treatments and strategic partnerships.
The company offers the FDA-approved Exelon® Patch, a transdermal system designed to improve patient compliance in treating mild to severe Alzheimer’s.
In 2023, Novartis invested in AstronauTx, a biotech firm specializing in neurodegenerative diseases, contributing to a $61 million Series A funding round to advance new Alzheimer’s therapies.
Additionally, Novartis is progressing NIO752, an antisense oligonucleotide targeting tau protein, currently in Phase 1 trials, demonstrating its commitment to addressing tau-related neurodegeneration.
These efforts highlight Novartis’s focus on expanding its Alzheimer’s treatment portfolio through cutting-edge research and strategic investments.
Geographical Presence
Novartis AG, headquartered in Basel, Switzerland, operates in over 140 countries, with a strong presence in North America, Europe, Asia-Pacific, and Latin America.
The company has significant operations in the U.S., with research and manufacturing sites, and in Europe, including Switzerland and the UK.
In Asia, Novartis has expanded its footprint in China and India, investing heavily in both regions. The company also continues to grow in Latin America, collaborating with local healthcare systems.
Novartis has bolstered its global reach through strategic acquisitions, such as the purchase of Advanced Accelerator Applications in 2017, and remains focused on expanding in key markets like China.
Recent Development
- In September 2024, Novartis sold Worldwide Rights to DESFERAL (deferoxamine) to MITEM Pharma.
- In July 2023, Novartis acquired DTx Pharma, a San Diego biotech firm developing siRNA therapies for neuroscience using its FALCON platform.
Johnson-n-Johnson
Company Overview
| Establishment Year | 1886 |
| Headquarter | New Brunswick, New Jersey, U.S. |
| Key Management | Joaquin Duato (CEO) |
| Revenue (US$ Bn) | $ 85.1 B (2023) |
| Headcount | ~ 134,400 (2023) |
| Website | https://www.jnj.com/ |
About Johnson & Johnson
Johnson & Johnson (J&J) continues to advance Alzheimer’s disease treatments through research and partnerships.
In October 2024, J&J discontinued several neuroscience programs, including a Phase II trial of seltorexant for Alzheimer ‘s-related agitation, as part of a portfolio shift.
Simultaneously, AbbVie announced plans to acquire Aliada Therapeutics, co-founded by J&J’s venture arm, for $1.4 billion. Aliada’s lead treatment, ALIA-1758, an anti-amyloid beta antibody, is in Phase I trials.
J&J’s Janssen Pharmaceuticals is also advancing ACI-35.030, a tau-targeting vaccine, in collaboration with AC Immune, with promising early Phase 1b/2a results. These moves highlight J&J’s commitment to Alzheimer’s innovation.
Geographical Presence
Johnson & Johnson (J&J) operates in over 60 countries, with products distributed in more than 175 nations.
The company has a significant presence in North America, particularly in the U.S. and Canada, as well as in Europe, including key markets such as the UK, Germany, and France.
In Asia-Pacific, J&J operates in countries like Japan, China, and India, while in Latin America, it has a strong footprint in Brazil, Mexico, and Argentina.
Manufacturing, research, and distribution facilities across these regions support the company’s global reach.
J&J’s strategic acquisitions and investments, particularly in emerging markets, further enhance its global healthcare access and product offerings.
Recent Developments
- In October 2024, J&J launched the VOLT Variable Angle Optimized Locking Technology Plating System.
- In January 2024, J&J acquired Ambrx Biopharma, a clinical-stage company specializing in synthetic biology for next-generation ADCs.
Bristol-Myers-Squibb
Company Overview
| Establishment Year | 1887 |
| Headquarter | Princeton, New Jersey, U.S. |
| Key Management | Chris Boerner (CEO) |
| Revenue (US$ Bn) | $ 45.01 Billion (2023) |
| Headcount | ~ 34,000 (2023) |
| Website | http://bms.com/ |
About Bristol Myers Squibb
Bristol Myers Squibb (BMS) is actively engaged in the Alzheimer’s disease therapeutics sector through strategic collaborations and acquisitions.
In June 2021, BMS agreed with Prothena Corporation, paying $80 million for exclusive rights to PRX005, an experimental antibody targeting tau proteins associated with Alzheimer’s pathology.
In September 2024, BMS acquired Karuna Therapeutics for $14 billion, gaining access to Cobenfy (formerly KarXT), a novel muscarinic receptor agonist initially developed for schizophrenia and now under investigation for Alzheimer ‘s-related psychosis.
These initiatives underscore BMS’s commitment to expanding its neuroscience portfolio and addressing unmet needs in Alzheimer’s disease treatment.
Geographical Presence
Bristol Myers Squibb (BMS) has a robust global presence, with research and development (R&D) facilities in the United States, Europe, and Asia, focusing on areas like cancer, immunology, and cardiovascular diseases. Key R&D hubs are located in New Jersey, Massachusetts, Spain, France, Japan, China, and India.
The company operates advanced manufacturing sites in the U.S., Ireland, Switzerland, and the Netherlands, supporting the production of biologics and small molecule therapies.
BMS also maintains significant commercial operations across the U.S., Europe, and Asia, ensuring broad access to its innovative medicines for patients worldwide.
Recent Developments
- In December 2023, Bristol Myers Squibb acquired Karuna Therapeutics, a biopharmaceutical company focused on developing transformative medicines for psychiatric and neurological conditions.
- In June 2021, Bristol Myers Squibb paid $80 million for exclusive rights to an Alzheimer’s drug developed by Prothena, a biotech focused on dysfunctional proteins.
Sanofi
Company Overview
| Establishment Year | 1973 |
| Headquarter | Paris, France |
| Key Management | Paul Hudson (CEO) |
| Revenue (US$ Bn) | $ 50.2 Billion (2022) |
| Headcount | ~ 86,088 (2023) |
| Website | http://www.sanofi.com/ |
About Sanofi
Sanofi S.A., a key player in Alzheimer’s therapeutics, has pursued strategic collaborations to enhance treatment options.
In 2018, it partnered with Denali Therapeutics to develop RIPK1 inhibitors for neurological diseases but paused clinical trials of DNL747 in 2020, shifting focus to the more promising DNL788. Recently, Sanofi expanded its portfolio through acquisitions and investments.
In January 2024, it agreed to acquire Inhibrx for up to $2.2 billion, gaining access to INBRX-101, a potential treatment for Alpha-1 Antitrypsin Deficiency.
Additionally, in October 2024, Sanofi entered negotiations to transfer a 50% stake in its consumer healthcare unit, Opella, to Clayton, Dubilier & Rice while retaining a significant share.
These moves highlight Sanofi’s commitment to strengthening its therapeutic offerings and industry position.
Geographical Presence
Sanofi S.A., headquartered in Paris, France, is a global leader in healthcare, operating in over 100 countries.
The company has a strong presence across regions, with Europe being a key market, contributing significant revenue and hosting major manufacturing facilities.
The United States remains its largest market, with substantial R&D and manufacturing operations. In the Asia-Pacific region, Sanofi has expanded with investments in Singapore and India.
Additionally, the company maintains a presence in Latin America. It operates numerous manufacturing and research facilities worldwide, including in France, the U.S., and India, reinforcing its ability to serve diverse global markets.
Recent Developments
- In October 2024, Sanofi sold a 50% stake in its consumer health business, Opella, to Clayton Dubilier Rice.
- In April 2023, Sanofi acquired Provention Bio, adding TZIELD, a groundbreaking type 1 diabetes therapy, to its General Medicines portfolio.
Pfizer
Company Overview
| Establishment Year | 1849 |
| Headquarter | New York City, U.S. |
| Key Management | Albert Bourla (CEO) |
| Revenue (US$ Bn) | $ 58.5 Billion (2023) |
| Headcount | ~ 88,000 (2023) |
| Website | http://pfizer.com/ |
About Pfizer
Pfizer Inc. has actively pursued Alzheimer’s disease therapeutics through various research initiatives and collaborations.
In 2009, it began Phase 1 studies for PF-04360365, a monoclonal antibody, and dimebon in combination with donepezil.
However, a 2010 Phase 3 trial of dimebon failed, leading to its discontinuation. Despite expanding its R&D investment strategy in 2018 to explore neurodegenerative diseases, Pfizer announced it would cease Alzheimer’s and Parkinson’s research to refocus resources.
In recent years, Pfizer’s strategy shifted towards acquisitions, including the $43 billion purchase of Seagen Inc. in 2023, enhancing its oncology portfolio while not directly impacting Alzheimer’s research.
Geographical Presence
Pfizer Inc. operates in over 100 countries, with a significant presence in regions such as the United States, which accounts for nearly 46% of its revenue and developed European markets, including the UK, Germany, and France.
The company also has strong operations in developed markets like Japan, Canada, and Australia and is expanding rapidly in emerging markets, including China, India, Brazil, and Russia.
Pfizer’s global manufacturing network includes key sites in the U.S., Belgium, and Ireland, which supports its broad portfolio of medicines and vaccines.
This extensive geographical presence enables Pfizer to address diverse healthcare needs and maintain a strong position in the global pharmaceutical industry.
Recent Development
- In October 2024, Pfizer partnered with the NFL to become an official pain relief partner of the NFL in Canada.
- In December 2023, Pfizer acquired Seagen Inc., a biotechnology company focused on developing transformative cancer medicines.
Teva-Pharmaceutical
Company Overview
| Establishment Year | 1901 |
| Headquarter | Tel Aviv, Israel |
| Key Management | Richard Francis (CEO) |
| Revenue (US$ Bn) | $ 15.8 Billion (2023) |
| Headcount | ~ 37,851 (2023) |
| Website | http://www.tevapharm.com/ |
About Teva Pharmaceutical
Teva Pharmaceutical Industries Ltd. has actively pursued advancements in Alzheimer’s disease therapeutics through strategic collaborations and acquisitions.
In October 2021, Teva entered into a licensing agreement with MODAG GmbH to develop anle138b, a small molecule targeting pathological alpha-synuclein oligomers, with potential applications in neurodegenerative diseases, including Alzheimer’s.
This collaboration underscores Teva’s commitment to expanding its portfolio in neurodegenerative disease treatments.
Additionally, Teva’s acquisition of Auspex Pharmaceuticals in 2015 enhanced its central nervous system (CNS) pipeline, potentially impacting Alzheimer’s research.
These strategic initiatives reflect Teva’s dedication to addressing unmet needs in Alzheimer’s disease therapeutics.
Geographical Presence
Teva Pharmaceutical Industries Ltd., headquartered in Petah Tikva, Israel, operates in over 60 countries, including a significant presence in North America, Europe, and various international markets.
In North America, Teva maintains a strong foothold, particularly in the U.S., where it offers a wide range of generic and specialty medicines.
Its European operations, based in the Netherlands, span over 30 countries, providing a diverse portfolio of pharmaceuticals.
The company’s global manufacturing network includes more than 53 facilities across 33 countries, supporting its extensive market reach.
Teva’s international operations serve millions of people, reinforcing its role as a key player in the global pharmaceutical industry.
Recent Developments
- In October 2024, Teva Pharmaceuticals introduced a generic version of Sandostatin LAR Depot in the US.
- In October 2021, Teva Pharmaceuticals and MODAG GmbH announced a strategic collaboration for the worldwide licensing and development of anle138b and sery433.
AbbVie
Company Overview
| Establishment Year | 2012 |
| Headquarter | North Chicago, Illinois, United States |
| Key Management | Richard A. Gonzalez (CEO) |
| Revenue (US$ Bn) | $ 50.3 Billion (2023) |
| Headcount | ~ 50,000 (2023) |
| Website | http://abbvie.com/ |
About AbbVie
AbbVie Inc. has strategically expanded its Alzheimer’s disease therapeutics portfolio through targeted acquisitions and collaborations.
In October 2024, AbbVie announced plans to acquire Aliada Therapeutics for $1.4 billion, aiming to enhance its neuroscience pipeline with Aliada’s lead compound, ALIA-1758, an anti-pyroglutamate amyloid beta antibody in development for Alzheimer’s treatment.
This acquisition also grants AbbVie access to Aliada’s novel blood-brain barrier-crossing technology, potentially improving the delivery of therapeutics to the central nervous system.
Earlier, in December 2023, AbbVie agreed to acquire Cerevel Therapeutics for $8.7 billion, thereby adding a range of assets targeting psychiatric and neurological disorders, including Alzheimer’s disease, to its portfolio.
These strategic moves underscore AbbVie’s commitment to advancing treatments for Alzheimer’s disease and strengthening its position in the neuroscience sector.
Geographical Presence
AbbVie Inc. operates in over 170 countries, with a strong presence across key global regions. Headquartered in North Chicago, the company has a significant footprint in North America, including the United States and Canada.
In Europe, AbbVie is established in countries such as Germany, France, Italy, Spain, and the United Kingdom.
It also maintains operations in the Asia-Pacific region, notably in Japan, China, and Australia, and has a growing presence in Latin America, particularly in Brazil and Mexico.
Additionally, AbbVie is active in the Middle East and Africa, enhancing its global distribution network and meeting diverse regional healthcare needs.
Recent Developments
- In October 2024, AbbVie received FDA approval for VYALEV, a 24-hour infusion therapy for motor fluctuations in advanced Parkinson’s disease.
- In December 2023, AbbVie acquired Cerevel Therapeutics, enhancing its neuroscience portfolio with candidates for schizophrenia, Parkinson’s, and mood disorders.
